Hummingbird Bioscience Holdings Pte.
Latest round
- Series C
Last raised
- Dec 2021
Total raised
- $160M
Investors
- 23
About Hummingbird Bioscience Holdings Pte.
Founded in 2015 by CEO Piers Ingram and Jerome Boyd-Kirkup, and based in Singapore, Hummingbird Bioscience Pte. Ltd. also known as Hummingbird Bioscience Holdings Pte. Ltd. is a clinical-stage biotech company that offers a new generation of transformative precision medicines against hard-to-drug targets focusing on HER3, a protein implanted in cancers. The company operates across the US and Singapore., Ltd. to identify solid tumor patients in China that are eligible for Hummingbird’s HER3- directed antibody, HMBD-001. In 2021, Hummingbird Bioscience Holdings Pte. Ltd. As of 2021, the company employs 25 employees. Hummingbird Bioscience utilizes computational biology tools to understand the structure and function of proteins involved in disease mechanisms and identify therapeutic targets, strategies, and epitopes. The company’s Rational Antibody Discovery platform consists of mABHits and mAbPredict that uses an immuno-engineering system to manipulate an immune response to control the production of antibodies against the optimal yet elusive epitopes on HER3, a part of the EGFR family and a protein implicated in many kinds of cancer, wherein the resultant antibodies potently blocked the HER3 activation to stop tumor cell growth., viral proteins. The company has also identified biomarkers indicative of the patient population that could benefit the most from HER3 therapy such as patients whose tumors carry neuregulin 1 (NRG1)- fusions. Hummingbird’s pipeline consists of HMBD-001, the flagship precision therapy program that targets HER3, HMBD-002, an anti-VISTA (V-domain immunoglobulin suppressor of T cell activation) monoclonal antibody to inhibit tumor growth, and HMBD-009, that targets BCMA, and TACI proteins expressed on tumor cells in multiple myeloma. Additionally, the firm also offers HMBD-011 which is in the pre-clinical stage. The company plans on entering HMBD-001 in Phase 1 clinical trials by the end of 2021 and progressing its partnership with Novogene to identify biomarkers beyond NRG1-fusions.
Who invested in Hummingbird Bioscience Holdings Pte.
23 investors across 3 rounds
See all investors in Hummingbird Bioscience Holdings Pte.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hummingbird Bioscience Holdings Pte.
Who invested in Hummingbird Bioscience Holdings Pte.?
Hummingbird Bioscience Holdings Pte. has 23 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hummingbird Bioscience Holdings Pte. raised?
Hummingbird Bioscience Holdings Pte. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Hummingbird Bioscience Holdings Pte. last raise money?
Hummingbird Bioscience Holdings Pte.'s most recent round on record is a Series C, in Dec 2021.
What does Hummingbird Bioscience Holdings Pte. do?
Founded in 2015 by CEO Piers Ingram and Jerome Boyd-Kirkup, and based in Singapore, Hummingbird Bioscience Pte.
Where is Hummingbird Bioscience Holdings Pte. headquartered?
Hummingbird Bioscience Holdings Pte. is headquartered in Singapore, Singapore.
Which VCs invest in companies like Hummingbird Bioscience Holdings Pte.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hummingbird Bioscience Holdings Pte.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Hummingbird Bioscience Holdings Pte.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.